scholarly journals Residual bioburden in reprocessed side-view endoscopes used for endoscopic retrograde cholangiopancreatography (ERCP)

2013 ◽  
Vol 1 (01) ◽  
pp. 12-16 ◽  
Author(s):  
D. Ubhayawardana ◽  
J. Kottahachchi ◽  
M. Weerasekera ◽  
I. Wanigasooriya ◽  
S. Fernando ◽  
...  
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Side View ◽  
Endoscopic Retrograde

scholarly journals Intraductal Ultrasonography in Pancreatobiliary Diseases

2017 ◽  
Vol 08 (03) ◽  
pp. 115-118 ◽  
Author(s):  
Rinkesh Kumar Bansal ◽  
Narendra S. Choudhary ◽  
Rajesh Puri ◽  
Zubin Sharma ◽  
Saurabh Patle ◽  
...  
Keyword(s):  
Real Time ◽  
Endoscopic Retrograde Cholangiopancreatography ◽  
Side View ◽  
High Quality ◽  
Endoscopic Retrograde ◽  
Intraductal Ultrasonography ◽  
Current Review ◽  
Local Staging ◽  
Biopsy Channel ◽  
Quality Imaging

ABSTRACTIntraductal ultrasonography (IDUS) utilizes probe catheter and operates at a higher frequency (12–30 MHz). It can be passed down the biopsy channel of a side‑view endoscope during endoscopic retrograde cholangiopancreatography, and it provides real‑time, high‑quality imaging of pancreatobiliary ducts and the surrounding structures. IDUS has been used in defining choledocholithiasis, evaluating biliary as well as pancreatic strictures or thickening, and local staging of tumor. We shall discuss the utility of IDUS in the current review.

Efficacy of octreotide (Octrade) for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

2020 ◽  
Vol 1 (30) ◽  
pp. 30-36
Author(s):  
E. A. Krylova ◽  
D. V. Aleinik
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Intravenous Infusion ◽  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Continuous Intravenous Infusion ◽  
Endoscopic Retrograde ◽  
Pancreatic Enzyme Secretion

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.

Sign in / Sign up

Export Citation Format

Share Document